Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical hematoporphyrin photodynamic therapy plus mitomycin for high-risk non-muscle-invasive bladder cancer
ChiCTR2500114725Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by Shanghai General Hospital. Primary endpoints: Recurrence-free survival and Complete remission rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2500114725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114725.